Cadila Pharmaceuticals Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Cadila Pharmaceuticals Limited Pharmaceutical Export Portfolio Dataset — 15 Products, $20.2M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Cadila Pharmaceuticals Limited — Pharmaceutical Exporter Profile (2026) | 15 Products, $20.2M Trade | TransData Nexus

Cadila Pharmaceuticals Limited

Indian Pharmaceutical Exporter · Cardiovascular Specialist · $20.2M Total Trade · DGFT Verified

Cadila Pharmaceuticals Limited is an Indian pharmaceutical exporter with a total trade value of $20.2M across 15 products in 11 therapeutic categories. Based on 908 verified export shipments from Indian Customs (DGFT) records, Cadila Pharmaceuticals Limited is the #1 Indian exporter in 1 product including Verapamil. Top exports include Mebendazole ($2.9M), Verapamil ($2.6M), Folic ($2.6M).

Cadila Pharmaceuticals Limited — Export Portfolio & Destination Treemap

Cadila Pharmaceuticals Limited pharmaceutical export portfolio — 15 products across 11 therapeutic categories. Source: Indian Customs (DGFT).

Who is Cadila Pharmaceuticals Limited? — Company Overview & Market Position

Cadila Pharmaceuticals Limited, established in 1951 by Indravadan A. Modi, is a prominent Indian multinational pharmaceutical company headquartered in Ahmedabad, Gujarat. The company specializes in the development and manufacturing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, across various therapeutic categories. Cadila Pharmaceuticals operates as a privately held entity, with its corporate identification number (CIN) being U24231GJ1991PLC015132. As of March 2026, the company employs approximately 6,096 individuals. The official website for Cadila Pharmaceuticals is www.cadilapharma.com.

In the fiscal year ending March 31, 2024, Cadila Pharmaceuticals reported an annual revenue of $433.44 million USD and a net profit of $11.8 million USD. The company's authorized capital stands at ₹1,206.5 million, with a paid-up capital of ₹800.1 million. Cadila Pharmaceuticals has a significant presence in over 100 countries, with a workforce exceeding 9,000 employees globally.

What Does Cadila Pharmaceuticals Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Mebendazole$2.9M

Product Portfolio — Top 15 by Export Value

Cadila Pharmaceuticals Limited exports 15 pharmaceutical products across 11 therapeutic categories. Market leader (#1 exporter) in 1 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Mebendazole	Antimalarial & Antiparasitic	$2.9M	116	19.6%	2
2	Verapamil	Cardiovascular	$2.6M	53	2.3%	1
3	Folic	Nutritional Supplements	$2.6M	103	4.7%	4
4	Domperidone	Gastrointestinal	$1.7M	90	5.8%	5
5	Ethambutol	Tuberculosis Medications	$1.7M	34	0.1%	3
6	Fexofenadine	Antihistamines & Allergy	$1.6M	74	1.5%	15
7	Erythromycin	Antibiotics	$1.4M	69	1.8%	6
8	Enalapril	Cardiovascular	$1.1M	108	0.5%	10
9	Vildagliptin	Advanced Diabetes Medications	$1.0M	22	10.1%	2
10	Isoniazid	Tuberculosis Medications	$783.6K	32	0.0%	12
11	Cefpodoxime	Advanced Antibiotics	$688.9K	67	0.9%	8
12	Ranitidine	Gastrointestinal	$571.5K	58	4.5%	4
13	Ketorolac	Analgesics & Antipyretics	$570.3K	56	0.5%	14
14	Guaifenesin	Respiratory & OTC	$419.5K	18	1.6%	12
15	Metoclopramide	Gastrointestinal	$336.3K	8	1.5%	8

Cadila Pharmaceuticals Limited exports 15 pharmaceutical products across 11 therapeutic categories with a total export value of $20.2M. The company is the #1 Indian exporter in 1 product: Verapamil. The top category is Cardiovascular (18.7% of portfolio), followed by Antimalarial & Antiparasitic (14.5%), reflecting a diversified portfolio where the top 5 products account for only 57.6% of total value.

Cadila Pharmaceuticals Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Cadila Pharmaceuticals operates multiple manufacturing facilities to support its extensive product portfolio. The primary formulation manufacturing plant is located in Dholka, Gujarat, India, covering over 100 acres and holding USFDA approval. Another formulation facility is situated in Samba, Jammu & Kashmir, India, producing a range of dosage forms. Additionally, the company has an active pharmaceutical ingredient (API) manufacturing unit in Ankleshwar, Gujarat, India, which is USFDA-certified. Internationally, Cadila Pharmaceuticals has a formulation manufacturing facility in Addis Ababa, Ethiopia, which complies with WHO cGMP standards.

3Key Leadership

The leadership of Cadila Pharmaceuticals is headed by Rajiv Indravadan Modi, who serves as the Chairman and Managing Director. Under his guidance, the company has expanded its global footprint and diversified its product offerings. The Board of Directors includes key figures such as Ramesh Ratilal Choksi, who holds the position of Whole-Time Director, and Girdhar Prem Balwani, an Independent Director. The company's leadership team is committed to upholding high standards of corporate governance and ethical business practices.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Cadila Pharmaceuticals Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Cadila Pharmaceuticals has established a strong presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facilities in Dholka and Ankleshwar, Gujarat, are USFDA-approved, enabling the export of pharmaceutical formulations to the U.S. market. The facility in Dholka also meets stringent quality standards, facilitating access to European and UK markets. The company's commitment to quality is further demonstrated by its WHO cGMP-compliant facility in Addis Ababa, Ethiopia, which supports its operations in Africa. These regulatory approvals underscore Cadila Pharmaceuticals' dedication to maintaining high manufacturing standards and ensuring the safety and efficacy of its products in international markets.

2Emerging Markets

Cadila Pharmaceuticals has strategically expanded its footprint in emerging markets, particularly in Africa, Latin America, and Southeast Asia. The company's formulation manufacturing facility in Addis Ababa, Ethiopia, serves as a gateway to the African market, providing access to a region with growing healthcare needs. While specific details regarding operations in Latin America and Southeast Asia are limited, Cadila Pharmaceuticals' global outreach and commitment to innovation suggest potential growth opportunities in these regions. The company's adherence to international quality standards, such as WHO cGMP compliance, positions it favorably to meet the demands of emerging markets seeking high-quality pharmaceutical products.

Cadila Pharmaceuticals Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Cadila Pharmaceuticals' manufacturing facilities in Dholka and Ankleshwar, Gujarat, are registered with the U.S. Food and Drug Administration (FDA), allowing the company to export pharmaceutical formulations to the U.S. market. The Dholka facility holds USFDA approval, ensuring compliance with stringent manufacturing standards required for the U.S. market. The Ankleshwar facility is also USFDA-certified, indicating adherence to quality standards necessary for exporting APIs to the U.S. These FDA registrations reflect Cadila Pharmaceuticals' commitment to maintaining high-quality manufacturing processes and meeting the regulatory requirements of the U.S. market.

2WHO & EU GMP

Cadila Pharmaceuticals' manufacturing facility in Addis Ababa, Ethiopia, is compliant with the World Health Organization's Good Manufacturing Practices (WHO cGMP), ensuring that the company meets international standards for pharmaceutical manufacturing. While specific details regarding EU GMP certification are not provided, the company's adherence to WHO cGMP standards suggests a commitment to maintaining high-quality manufacturing processes that align with international regulatory expectations.

3CDSCO & Indian Regulatory

Cadila Pharmaceuticals Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Cadila Pharmaceuticals operates in a competitive landscape with several key players in the pharmaceutical industry. While specific market share comparisons are not provided, the company's diverse product portfolio and global manufacturing capabilities position it as a significant competitor in the market. The company's focus on innovation and adherence to international quality standards enable it to compete effectively across various therapeutic categories and geographic regions.

2Key Differentiators

Cadila Pharmaceuticals' key differentiators include its strong emphasis on research and development, leading to first-in-the-world innovations in areas such as lung cancer, tuberculosis, cardiovascular diseases, and gastroenterology. The company's state-of-the-art manufacturing facilities, compliant with international standards like USFDA, European Union, MHRA UK, WHO Geneva, and TGA Australia, further distinguish it in the market. Additionally, Cadila Pharmaceuticals' global outreach, with operations in over 100 countries and a workforce of more than 9,000 employees, enhances its competitive advantage.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Cadila Pharmaceuticals Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Cadila Pharmaceuticals has a track record of consistent export volume, with a total export value of $20.2 million USD and 908 shipments across 15 products in 11 therapeutic categories. The company's portfolio concentration is notable, with the top five products accounting for 57.6% of total exports. This concentration includes products such as Verapamil, Mebendazole, Folic, Domperidone, and Ethambutol, which are leaders in their respective markets.

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Cadila Pharmaceuticals Limited

How many pharmaceutical products does Cadila Pharmaceuticals Limited export from India?

Cadila Pharmaceuticals Limited exports 15 pharmaceutical products across 11 therapeutic categories. The top exports are Mebendazole ($2.9M), Verapamil ($2.6M), Folic ($2.6M), Domperidone ($1.7M), Ethambutol ($1.7M). Total export value is $20.2M.

What is Cadila Pharmaceuticals Limited's total pharmaceutical export value?

Cadila Pharmaceuticals Limited's total pharmaceutical export value is $20.2M, based on 908 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Cadila Pharmaceuticals Limited the #1 Indian exporter?

Cadila Pharmaceuticals Limited is the #1 Indian exporter in 1 products: Verapamil (2.3% market share).

What therapeutic categories does Cadila Pharmaceuticals Limited cover?

Cadila Pharmaceuticals Limited exports across 11 therapeutic categories. The largest are Cardiovascular (18.7%, 2 products), Antimalarial & Antiparasitic (14.5%, 1 products), Nutritional Supplements (13.1%, 1 products).

Get Full Cadila Pharmaceuticals Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.